Gilead is withdrawing the accelerated approval for its blockbuster antibody-drug conjugate Trodelvy for bladder cancer after ...
The results of Gilead's much-anticipated TROPiCS-02 study of Trodelvy are in, and while the company says top-line data are positive, its guarded stance has rung some alarm bells. In the study ...
Trodelvy (sacituzumab govitecan-hziy) is a brand-name IV infusion prescribed for certain cancers in adults. As with other drugs, Trodelvy can cause side effects, such as diarrhea, hair loss ...
Trodelvy (sacituzumab govitecan-hziy) is a prescription drug used to treat certain breast and bladder cancers. Scientists have studied the success rate of Trodelvy and found it to be effective in ...
7-10, 2024 in San Diego, Calif. Data to be highlighted across three oral presentations include: initial results from two cohorts of the EVOKE-02 study of Trodelvy ® (sacituzumab govitecan-hziy ...